Characterization of the therapeutic effect of antibodies targeting the Ebola glycoprotein using a novel BSL2-compliant rVSVΔG-EBOV-GP infection model

References

• Leligdowicz A, Fischer 2nd WA, Uyeki TM, et al. Ebola virus disease and critical illness. Crit Care. 2016 Jul;20(217):217. PMID:27468829.
   Google Scholar
• Billioux B, Nath A, Stavale EJ, et al. Cerebrospinal fluid examination in survivors of ebola virus disease. JAMA Neurol. 2017;74(9):1141–1143.
   Web of Science ®Google Scholar
• Jacobs M, Rodger A, Bell DJ, et al. Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet. 2016 Jul 30;388(10043):498–503.
   PubMed Web of Science ®Google Scholar
• Sagui E, Janvier F, Baize S, et al. Severe Ebola virus infection with encephalopathy: evidence for direct virus involvement. Clin Infect Dis. 2015;61(10):1627–1628.
   Web of Science ®Google Scholar
• Varkey JB, Shantha JG, Crozier I, et al. Persistence of Ebola virus in ocular fluid during convalescence. N Engl J Med. 2015 Jun 18;372(25):2423–2427.
   PubMed Web of Science ®Google Scholar
• Howlett PJ, Walder AR, Lisk DR, et al. Case series of severe neurologic sequelae of Ebola virus disease during epidemic, Sierra Leone. Emerg Infect Dis. 2018 Aug;24(8):1412–1421.
   Web of Science ®Google Scholar
• Scott JT, Sesay FR, Massaquoi TA, et al. Post-Ebola syndrome, Sierra Leone. Emerg Infect Dis. 2016 Apr;22(4):641–646.
   PubMed Web of Science ®Google Scholar
• Group PIS, Sneller MC, Reilly C, et al. A longitudinal study of Ebola sequelae in Liberia. N Engl J Med. 2019 Mar 7;380(10):924–934.
   Web of Science ®Google Scholar
• MacDermott NE, Bausch DG. Virus persistence and recrudescence after Ebola virus disease: what are the risks to healthcare workers? J Hosp Infect. 2016 Oct;94(2):113–115.
   Web of Science ®Google Scholar
• Malvy D, McElroy AK, de Clerck H, et al. Ebola virus disease. Lancet. 2019 Mar 2;393(10174):936–948.
   PubMed Web of Science ®Google Scholar
• Wong G, Qiu X, Bi Y, et al. More challenges from ebola: infection of the central nervous system. J Infect Dis. 2016 Oct 15;214(suppl 3):S294–S296.
   Google Scholar
• Christie A, Neatherlin JC, Nichol ST, et al. Ebola response priorities in the time of Covid-19. N Engl J Med. 2020 Sep 24;383(13):1202–1204.
   Web of Science ®Google Scholar
• Simmons G, Reeves JD, Grogan CC, et al. DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology. 2003 Jan 5;305(1):115–123.
   PubMed Web of Science ®Google Scholar
• Shimojima M, Takada A, Ebihara H, et al. Tyro3 family-mediated cell entry of Ebola and Marburg viruses. J Virol. 2006 Oct;80(20):10109–10116.
   PubMed Web of Science ®Google Scholar
• Kondratowicz AS, Lennemann NJ, Sinn PL, et al. T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and lake Victoria Marburgvirus. Proc Natl Acad Sci U S A. 2011 May 17;108(20):8426–8431.
   Web of Science ®Google Scholar
• Takada A, Watanabe S, Ito H, et al. Downregulation of beta1 integrins by Ebola virus glycoprotein: implication for virus entry. Virology. 2000 Dec 5;278(1):20–26.
   PubMed Web of Science ®Google Scholar
• Bray M, Geisbert TW. Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int J Biochem Cell Biol. 2005 Aug;37(8):1560–1566.
   PubMed Web of Science ®Google Scholar
• Wang H, Shi Y, Song J, et al. Ebola viral glycoprotein bound to its endosomal receptor niemann-pick C1. Cell. 2016 Jan 14;164(1-2):258–268.
   Web of Science ®Google Scholar
• Gonzalez-Gonzalez E, Alvarez MM, Marquez-Ipina AR, et al. Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead. Crit Rev Biotechnol. 2017 Feb;37(1):53–68.
   PubMed Web of Science ®Google Scholar
• Pavot V. Ebola virus vaccines: where do we stand? Clin Immunol. 2016 Dec;173:44–49.
   Web of Science ®Google Scholar
• Aschenbrenner DS. Monoclonal antibody approved to treat ebola. Am J Nurs. 2021 Apr 1;121(4). PMID:33755619.
   Web of Science ®Google Scholar
• Hansen F, Feldmann H, Jarvis MA. Targeting Ebola virus replication through pharmaceutical intervention. Expert Opin Investig Drugs. 2021 Mar;30(3):201–226.
   PubMed Web of Science ®Google Scholar
• Saito T, Maruyama J, Nagata N, et al. A surrogate animal model for screening of Ebola and Marburg glycoprotein-targeting drugs using pseudotyped vesicular stomatitis viruses. Viruses. 2020 Aug 22;12(9). PMID:32842671
   Web of Science ®Google Scholar
• Claire MC S, Ragland DR, Bollinger L, et al. Animal models of Ebolavirus infection. Comp Med. 2017 Jun 1;67(3):253–262.
   Web of Science ®Google Scholar
• McWilliams IL, Kielczewski JL, Ireland DDC, et al. Pseudovirus rVSVDeltaG-ZEBOV-GP infects neurons in retina and CNS, causing apoptosis and neurodegeneration in neonatal mice. Cell Rep. 2019 Feb 12;26(7):1718–1726.e4.
   Web of Science ®Google Scholar
• Luke T, Bennett RS, Gerhardt DM, et al. Fully human immunoglobulin G from transchromosomic bovines treats nonhuman primates infected with Ebola virus Makona isolate. J Infect Dis. 2018 Nov 22;218(suppl_5):S636–S648.
   PubMedGoogle Scholar
• Dye JM, Wu H, Hooper JW, et al. Production of potent fully human polyclonal antibodies against Ebola Zaire virus in transchromosomal cattle. Sci Rep. 2016 Apr 25;6(24897). PMID:27109916.
   Google Scholar
• Manangeeswaran M, Ireland DDC, Verthelyi D. Zika (PRVABC59) infection is associated with T cell infiltration and neurodegeneration in CNS of immunocompetent neonatal C57Bl/6 mice. PLoS Pathog. 2016;12(11). PMID:27855206.
   Web of Science ®Google Scholar
• Ireland DDC, Manangeeswaran M, Lewkowicz AP, et al. Long-term persistence of infectious Zika virus: inflammation and behavioral sequela in mice. PLoS Pathog. 2020;16(12). PMID:33301527.
   Web of Science ®Google Scholar
• Jacob ST, Crozier I, Fischer WA, et al. Ebola virus disease. Nat Rev Dis Primers. 2020 Feb 20;6(1). PMID:32080199.
   Web of Science ®Google Scholar
• Liu DX, Perry DL, Cooper TK, et al. Peripheral neuronopathy associated with Ebola virus infection in rhesus macaques: A possible cause of neurological signs and symptoms in human Ebola patients. J Infect Dis. 2020 Jun; 222(10):1745–1755.
   Web of Science ®Google Scholar
• Billioux BJ, Smith B, Nath A. Neurological complications of Ebola virus infection. Neurotherapeutics. 2016 Jul;13(3):461–470.
   Web of Science ®Google Scholar
• de Greslan T, Billhot M, Rousseau C, et al. Ebola virus-related encephalitis. Clin Infect Dis. 2016 Oct 15;63(8):1076–1078.
   Web of Science ®Google Scholar
• Billioux BJ, Nath A, Stavale EJ, et al. Cerebrospinal fluid examination in survivors of Ebola virus disease. JAMA Neurol. 2017 Sep 1;74(9):1141–1143.
   Web of Science ®Google Scholar
• Pattyn S, van der Groen G, Jacob W, et al. Isolation of Marburg-like virus from a case of haemorrhagic fever in Zaire. Lancet. 1977 Mar 12;309(8011):573–574.
   Google Scholar
• van der Groen G, Jacob W, Pattyn SR. Ebola virus virulence for newborn mice. J Med Virol. 1979;4(3):239–240.
   PubMed Web of Science ®Google Scholar
• Chan M, Leung A, Griffin BD, et al. Generation and Characterization of a mouse-adapted Makona variant of Ebola virus. Viruses. 2019 Oct 26;11(11). PMID:31717793.
   Web of Science ®Google Scholar
• Garbutt M, Liebscher R, Wahl-Jensen V, et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol. 2004 May;78(10):5458–5465.
   PubMed Web of Science ®Google Scholar
• Feuer R, Pagarigan RR, Harkins S, et al. Coxsackievirus targets proliferating neuronal progenitor cells in the neonatal CNS. J Neurosci. 2005 Mar 2;25(9):2434–2344.
   Google Scholar
• Miner Jonathan J, Diamond Michael S. Understanding How Zika Virus Enters and Infects Neural Target Cells. Cell Stem Cell. 2016; 18(5):559–560.
   Google Scholar
• Lee AJ, Ashkar AA. The Dual Nature of Type I and Type II Interferons. Frontiers in immunology. 2018; 9(2061). PMID:30254639.
   Google Scholar
• Billioux BJ. Neurological complications and sequelae of Ebola virus disease. Curr Infect Dis Rep. 2017 May;19(5). PMID:28391498.
   Web of Science ®Google Scholar
• Etard JF, Sow MS, Leroy S, et al. Multidisciplinary assessment of post-Ebola sequelae in Guinea (postebogui): an observational cohort study. Lancet Infect Dis. 2017 May;17(5):545–552.
   PubMed Web of Science ®Google Scholar
• Presumey J, Bialas AR, Carroll MC. Advances in immunology. Adv Immunol. 2017;135:53–79.
   Google Scholar
• Abellanas MA, Zamarbide M, Basurco L, et al. Midbrain microglia mediate a specific immunosuppressive response under inflammatory conditions. J Neuroinflammation. 2019 Nov 22;16(233). PMID:31757220.
   Google Scholar
• Hegarty SV, Sullivan AM, O’Keeffe GW. Midbrain dopaminergic neurons: a review of the molecular circuitry that regulates their development. Dev Biol. 2013 Jul 15;379(2):123–138.
   PubMed Web of Science ®Google Scholar
• Vasek MJ, Garber C, Dorsey D, et al. A complement-microglial axis drives synapse loss during virus-induced memory impairment. Nature. 2016 Jun 23;534(7608):538–543.
   PubMed Web of Science ®Google Scholar